Ozempic shows lower cardiovascular risk vs Eli Lilly's Mounjaro: Novo Nordisk
Novo Nordisk says a real-world study found type 2 diabetes patients increasing Ozempic to 2 mg had a lower risk of major cardiovascular events than those switching to Eli Lilly’s Mounjaro
Reuters1 min read
Share

Add Emirates 24|7 to your Google News
Text Size:
